Ayyildiz Talat, Dolar Enver, Ugras Nesrin, Dizdar Oguzhan Sitki, Adim Saduman Balaban, Yerci Omer
Department of Gastroenterology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey E-mail :
Asian Pac J Cancer Prev. 2014;15(11):4711-6. doi: 10.7314/apjcp.2014.15.11.4711.
Adiponectin (ApN) is a complement C1q-related protein, mainly secreted from adipose tissue, that signals through ApN receptor 1 (Adipo-R1) and ApN receptor 2 (Adipo-R2). Low serum ApN concentrations are associated with obesity-related malignancies. However, there are very few studies on any prognostic role of ApN receptors in gastric cancer.
The aim of this study is to investigate the relationship between AdipoR1/R2 expression and early/advanced stage gastric cancer in terms of clinicopathologic characteristics and survival.
Eighteen patients with early and 39 with advanced stage gastric cancer who underwent surgical gastric resection were included in this study.
Adipo-R1 expression was low in 2 of the 18 patients with early stage gastric cancer (11.1%), while 4 had low Adipo-R2 expression (22.2%). In those with advanced stage gastric cancer, 7 of 39 had low Adipo-R1 expression (17.9%) and 16 had low Adipo-R2 expression (41%). Adipo-R2 expression was significantly higher (p=0.011) in moderately differentiated tumors when compared to well-differentiated tumors. While there was nearly a statistically significant relationship between TNM stage (T, tumor size; N, regional lymph node; M, whether distant metastases exist) and Adipo-R2 expression (p=0.054), there was no relationship between Adipo-R1/-R2 expression with tumor stage and survival.
Adipo-R1/-R2 expression has no prognostic significance of in early/advanced stage gastric cancer.
